Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study

NCT00705315 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00705315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00705315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2008
Completion date
June 30, 2010
Enrollment
46 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer